Show simple item record

dc.contributor.authorJordan, Kimberly R
dc.contributor.authorHall, Jessica K
dc.contributor.authorSchedin, Troy
dc.contributor.authorBorakove, Michelle
dc.contributor.authorXian, Jenny J
dc.contributor.authorDzieciatkowska, Monika
dc.contributor.authorLyons, Traci R
dc.contributor.authorSchedin, Pepper
dc.contributor.authorHansen, Kirk C
dc.contributor.authorBorges, Virginia F
dc.date.accessioned2020-11-30T20:37:59Z
dc.date.available2020-11-30T20:37:59Z
dc.date.issued2020-11-23
dc.identifier.urihttp://hdl.handle.net/10713/14156
dc.description.abstractBackground: Extracellular vesicles (EVs) are small membrane particles that contribute to cancer progression and metastases by transporting biologically significant proteins and nucleic acids. They may also serve as biomarkers of various disease states or important therapeutic targets. Breast cancer EVs have the potential to change the behavior of other cells in their microenvironment. However, the proteomic content of EVs isolated from young women’s breast cancer patients and the mechanisms underlying the influence of EVs on tumor cell behavior have not yet been reported. Methods: In our current translational studies, we compared the proteomic content of EVs isolated from invasive breast cancer cell lines and plasma samples from young women’s breast cancer (YWBC) patients and age-matched healthy donors using mass spectrometry. We analyzed the functionality of EVs in two dimensional tumor cell invasion assays and the gene expression changes in tumor cells after incubation with EVs. Results: We found that treatment with EVs from both invasive breast cancer cell lines and plasma of YWBC patients altered the invasive properties of non-invasive breast cancer cells. Proteomics identified differences between EVs from YWBC patients and healthy donors that correlated with their altered function. Further, we identified gene expression changes in non-invasive breast cancer cells after treatment with EVs that implicate the Focal Adhesion Kinase (FAK) signaling pathway as a potential targetable pathway affected by breast cancer-derived EVs. Conclusions: Our results suggest that the proteome of EVs from breast cancer patients reflects their functionality in tumor motility assays and may help elucidate the role of EVs in breast cancer progression.en_US
dc.description.sponsorshipThe research in this publication is funded by the following grants: the DOD Idea Award W81XWH-13-1-0078, the Breast Cancer Research Foundation-AACR Grant for Translational Research #09-06-26BORG, the Grohne Family Foundation, and the Conner Family Foundation to VB, and the following shared resource grants: NIH/NCI CCSG P30CA046934 (Protein Production/Mab/Tissue Culture Shared Resource) and the NIH/NCRR Colorado CTSI Grant UL1 RR025780.en_US
dc.description.urihttps://doi.org/10.1186/s13058-020-01363-xen_US
dc.language.isoenen_US
dc.publisherSpringer Natureen_US
dc.relation.ispartofBreast Cancer Research : BCRen_US
dc.subjectBreast canceren_US
dc.subjectExosomesen_US
dc.subjectExtracellular vesiclesen_US
dc.subjectNanoparticlesen_US
dc.subjectProteomicsen_US
dc.subjectYoung women’s breast canceren_US
dc.titleExtracellular vesicles from young women's breast cancer patients drive increased invasion of non-malignant cells via the Focal Adhesion Kinase pathway: a proteomic approach.en_US
dc.typeArticleen_US
dc.identifier.doi10.1186/s13058-020-01363-x
dc.identifier.pmid33225939
dc.source.volume22
dc.source.issue1
dc.source.beginpage128
dc.source.endpage
dc.source.countryUnited States
dc.source.countryUnited States
dc.source.countryEngland


This item appears in the following Collection(s)

Show simple item record